FDA ad­comm votes unan­i­mous­ly in fa­vor of ben­e­fit-risk pro­file of over-the-counter con­tra­cep­tive Opill

An FDA ad­comm vot­ed unan­i­mous­ly that the ben­e­fits of mak­ing Opill, a prog­estin-on­ly dai­ly oral con­tra­cep­tive, avail­able over-the-counter out­weighs the risks.

All 17 mem­bers of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER